Shares Held (Direct Ownership) 38K
n/a 3M change
n/a 12M change
Total Value Held N/A

Mayur Ian Somaiya Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 28 2025
SELL
Open market or private sale
-
14,900 Reduced 28.17%
38,000 Ordinary Shares
Jan 28 2025
BUY
Exercise of conversion of derivative security
$137,974 $9.26 p/Share
14,900 Added 21.98%
52,900 Ordinary Shares
Jan 27 2025
SELL
Open market or private sale
-
46,983 Reduced 55.29%
38,000 Ordinary Shares
Jan 27 2025
BUY
Exercise of conversion of derivative security
$435,062 $9.26 p/Share
46,983 Added 35.6%
84,983 Ordinary Shares
Jan 07 2025
BUY
Grant, award, or other acquisition
-
38,000 Added 50.0%
38,000 Ordinary Shares

Also insider at

TCRR
TCR2 THERAPEUTICS INC. Healthcare
MIS

Mayur Ian Somaiya

Chief Financial Officer
Cambridge, MA

Track Institutional and Insider Activities on NAMS

Follow NewAmsterdam Pharma Co N.V. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NAMS shares.

Notify only if

Insider Trading

Get notified when an New Amsterdam Pharma CO N.V. insider buys or sells NAMS shares.

Notify only if

News

Receive news related to NewAmsterdam Pharma Co N.V.

Track Activities on NAMS